NanoViricides Inc. (NNVC)

[JG36]

The latest PR highlights an amplified or enhanced capability the company has not had before, which is the ability to model more of the many binding points of a virus, rank those molecular solutions analytically for strongest affinity for cide attachment, synthesize a reduced subset of test cides, test those cides against the actual target virus in their new, in house, BSL2 facility (in the cGMP) for effectiveness, further distilling the test cide set, to a near optimal state before going forward with independent University animal studies; all the while capturing the QA/QC processes for more automated production batches for clinical trials and initial market entry. This is a much bigger crank than they have ever had before.

Actually NNVC has had the ability to tinker with its 'cides since its inception. That's what it has been doing for the past 10 years. What it can't do is make enough of any 'cide to get it through tox.